Medicine, Hematology

• 

  People

  • Administrative Positions

    • Ortel, Thomas Lee, Chief, Division of Hematology in the Department of Medicine

  • Professorships

    • Rosse, Wendell Franklyn, Florence McAlister Distinguished Professor Emeritus of Medicine, in the School of Medicine
    • Telen, Marilyn Jo, Wellcome Clinical Distinguished Professor of Medicine in Honor of R. Wayne Rundles, M.D.

  • Primary Appointments

    • Adam, Soheir Saeed, Associate Professor of Medicine
    • Addepalli, Srikala, Assistant Professor of Medicine
    • Arcasoy, Murat Osman, Professor of Medicine
    • Arepally, Gowthami Morey, Professor of Medicine
    • Berkowitz, Scott Darrell, Adjunct Associate Professor in the Department of Medicine
    • Blatt, Philip Mark, Adjunct Associate Professor in the Department of Medicine
    • Christensen, Dale Jay, Adjunct Associate Professor in the Department of Medicine
    • Crawford, Regina Denise, Assistant Professor of Medicine
    • De Castro, Laura Martina, Adjunct Associate Professor in the Department of Medicine
    • Fager, Ammon Milton, Assistant Professor of Medicine
    • Khandelwal, Sanjay, Assistant Professor in Medicine
    • Lee, Grace Ming, Assistant Professor of Medicine
    • Obieche, Jude C, Adjunct Associate in the Department of Medicine
    • Onwuemene, Oluwatoyosi Adefunke, Associate Professor of Medicine
    • Ortel, Thomas Lee, Professor of Medicine
    • Oyedeji, Charity, Assistant Professor of Medicine
    • Pericak-Vance, Margaret Ann, Adjunct Professor in the Department of Medicine
    • Rosse, Wendell Franklyn, Professor Emeritus of Medicine
    • Shah, Nirmish Ramesh, Associate Professor of Medicine
    • Strouse, John J., Associate Professor of Medicine
    • Telen, Marilyn Jo, Professor of Medicine
    • Weinberg, Joe Brice, Professor of Medicine
    • White Jr., James Patrick, Assistant Professor in Medicine
    • Zennadi, Rahima, Associate Professor in Medicine

  • Secondary Appointments

    • James, Andra Hohler, Consulting Professor in the Department of Medicine
    • Rothman, Jennifer Ann, Assistant Professor in Medicine
    • Tanabe, Paula J, Professor of Medicine
    • Welsby, Ian James, Professor of Medicine
• 

  Administers Grant

  • 12091912 INR Project
  • 2019 ASH RTAF
  • 2020 ASH RTAF
  • A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects W/ Essential Thromboythemia Who Are Resistant to or Intolerant of
  • A Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Subjects with Sickle Cell Disease
  • A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects with Congenital Fibrinogen Deficiency with a Prospective Followup Component
  • A Phase 2, Uncontrolled, Two-stage, Dose-escalations Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical activity of OMS721 in Adults with Thrombotic Microangiopathies
  • A Phase 2a, Randomised, Double Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-B thalassemia.
  • A Phase I/II Open-Label Safety and Dose-Finding Study of Adeno- Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B
  • A Whole Blood Collection from subjects clinicially diagnosed with PNH
  • AG348-C-011 extension study of adult subjects with Pyruvate Kinase Deficiency
  • ALXN1007-APS-201 An Open-label proof of concept Phase IIa trial of ALXN1007 for the treatment of non-criteria manifestations of Antiphospholipid Syndrome
  • AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE
  • Activation of Sickle Red Cell Adhesion
  • Adrenergic Receptor Variants and RBC Adhesion in SCD
  • American Society for Apheresis (ASFA) Heparin Induced Thrombocytopenia Registry
  • An Open label extension study of GBT440 administered orally to patients with sickle cell disease who have participated in GBT440 clinical trials
  • An Open-Label, Expanded Access Protocol for Patients with Sickle Cell Disease Who Have No Alternative Treatment Options - GBT 440-037
  • Anticoagulation Withdrawal in Antiphospholipid Syndrome
  • Apixaban for the Secondary prevention of Thromboembolism: a prospective, randomized, outcome pilot study amount patients with AntiphosPholipid Syndrome (ASTRO-APS)
  • Arginine, Nitric Oxide, and Severe Malaria
  • BIACORE 3000 Biosensor
  • Biological Significance of Protamine/Heparin Antibodies
  • Biological Significance of Protamine/Heparin Antibodies
  • Biological Significance of Protatmine/Heparin Antibodies
  • Burroughs Wellcome Travel Fund-Assessment of endothelial glycocalyz in normal children in a malaria endemic area of Africa
  • CSA - Pfizer 212511 B5201002 Phase 3 Randomized Multicenter Trial
  • Cellular Basis of HIT Immune Response in Cardiac Surgery
  • Central Carolinas Clinical Trials Collaboration (C3TC)
  • Cilia as a biomarker of CNS vascular health
  • Clinical Significance of protamine/heparin antibodies after CPB
  • Clinical Study Protocol for External Performance Evaluation of INNOVANCE Heparin on BCS XP, Method Comparison
  • Clinical Study Protocol for External Performance Evaluation of INNOVANCE Heparin on BCS XP¿Method Comparison
  • Complement and CR2/CD21 in the Immune Pathogenesis of HIT(R01)
  • Complement and Thrombosis in HIT
  • DU176b-A-U157/ A Phase 1, Open-Label, Single-Dose Non-Randomized Study To Evaluate Pharmacokinetics And Pharmacodynamics of Edoxaban In Pediatric Patients
  • Defining the role of therapeutic plasma exchange in heparin induced thrombocytopenia
  • Developing apheresis-specific outcomes to facilitate a multi-center study of therapeutic plasma exchange in heparin-induced thrombocytopenia
  • Duke-UNC Clinical Hematology and Transfusion Research Career Development Program
  • Duke/UNC Comprehensive Sickle Cell Center
  • Education and Mentoring to BRing Access to CarE SCD - EMBRACE SCD
  • Erythropoietin Receptor Regulation of Erythorpoiesis
  • Erythropoietin Receptors in Breast Cancer
  • Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial of MSY-188 injection in children with Sickle Cell disease experiencing vaso-occlusive crisis.
  • Evaluation of an Automated Information Extraction Tool for Identification of Venous Thromboembolism in Electronic Health Records (EHRs)
  • Evaluation, analysis, and dissemination of population-based cancer-associated venous thromboembolism (VTE) data
  • Extension of Hematologic & Clinical Genotype-Phenotype Associations in SCD Using Exome Chip & Metabolomic Analysis
  • External Evaluation of Assay Applications on The Sysmex CS2500 and CS-5100 Analyzer (Wave C)
  • FORMA FT4202-Hem-301 PRAISE PTV. An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE).
  • FORMA Therapeutics FT-4202
  • Factor XIII and Fibrinogen: Mechanisms of Genetic Risk in SCD-Related Priapism
  • Factors Involved in B-CAM/LU-Mediated Adhesion
  • Field Study to evaluate the activity of a site specific of B-Domain Deleted (BDD) pegylated recombinant FVIII protein (BAY 94-9027) in plasma samples measured with both chromogenic and one stage assa
  • Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)
  • GBT2104-131 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease (SCD) Experiencing Vaso-occlusive Crisis (VOCs)
  • GBT440-039 A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults with Sickle Cell Disease
  • GMI Technology vascular occlusion evaluation
  • HITSOVA Danaporiod vs Argatroban Phase III open-label, randomized trial
  • High-throughput Metabolite Profiling and Genetic Analyses to Identify Novel Predictive Biomarkers of SCD-related Complications
  • Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain
  • IL APS Fresh vs Frozen Clinical Agreement
  • IL ASP Clinical Outcome Study Agreement
  • IPA - James Nishimuta
  • IPA - Robert A. Nielsen
  • IPA - Robert Nielsen
  • IPA - Stephen H. Johnson
  • IPA - Youwei Chen
  • IPA - Youwei Chen
  • IPA - Youwei Chen
  • IPA for Youwei Chen
  • IPA-Youwei Chen
  • Immune Dysregulation in HIT
  • Impact of Daily Prophylaxis Dose Anticoagulation with a Factor Xa Inhibitor (Apixaban) in Patients with Sickle Cell Disease
  • Improving Pain in Sickle Cell Patients With Targeted Antithrombotic Therapy
  • Improving venous thromboembolism surveillance with natural language processing
  • Inducible NOS as a Treatment Target in CLL
  • L000013105 Protocol for Reagent Reproducibility of Liquid Anti-Xa Assay with Apixaban Calibrators on ACL TOP Analyzers
  • L0022511987 Rev 01 Hemosil, Liquid Anti-Xa Assay with Apixaban Calibrators and Controls Performance Evaluation and Fresh vs Frozen Stability Protocol on ACL. TOP 50 Family Series Analyzers
  • L0022511991 Rev 01 Liquid Anti-Xa Assay with Rivaroxaban Calibrators and Controls Performance Evaluation Protocol on ACL TOP
  • LOO22511932 Rev 01 Hemosil Direct Thrombin Inhibitor (DTI) Assay with Dabigatran Calibrators and Controls
  • Lateral Flow Hemoglobinopathies Test Development
  • MST-188-04 EVALUATION OF REPEAT ADMINISTRATION OF PURIFIED POLOXAMER 188 IN VASO-OCCLUSIVE CRISIS OF SICKLE CELL DISEASE (EPIC-E): AN OPEN-LABEL SAFETY EXTENSION TRIAL ASSESSING REPEAT ADMINISTRATION OF MST-188 (PURIFIED POLOXAMER 188) INJECTION IN
  • Minority Invest Post-Bacc Res. Supp. - T Jackson
  • Modeling the spectrum of HIT pathobiology
  • Molecular Biology Of Human Coagulation Factor V
  • Multi-site Clinical Laboratory Testing for SickleScan
  • Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age- and body-weight-adjusted rivaroxaban regimen in children with acute venous thromboembolism
  • NC DHHS Sickle Cell Contract
  • Neutrophil Activation Phenotypes in Healthy Subjects and Implications for Bacterial Clearance
  • Neutrophil activation responses to platelet factor 4/heparin immune complexes
  • Nitric Oxide and Malaria
  • Nitric Oxide and Microvascular Dysfunction in Severe Malaria
  • Obizur EU PASS. Prospective and retrospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice.
  • Open Label study to evaluate the safety and Pharmacokinetics of PF-06412528 in children 7-17 for treatment of moderate to severe pain
  • Outcome Modifying Genes in Sickle Cell Diseases
  • PC-ChFVIIa Proof of Concept Studies
  • PFIZER B0401016
  • POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A
  • PROPRANOLOL AS ANTI-ADHESIVE THERAPY IN SCD
  • Pathogenesis of Thrombosis in HIT
  • Phase 3, prospective, randomized, controlled study of prophylatic and on-demand treatment of cTTP with BAX930 (rADAMTS13)
  • Phase II Study of Propranolol as Anti-Adhesive Therapy in SCD
  • Phase II study of SEG101 in sickle cell disease patients with Prisprism (SPARTAN)
  • Phase II study to assess SEG101 in Sickle Cell Patients
  • Phase II, of oral SKI-O-703 in Chronic Immune Thrombocytopenia (ITP)
  • Phase III study of AG-348 in not regulary transfused adult subjects with Pyruvate kinase deficiency
  • Population-based Surveillance And Ourcomes of Venous Thromboembolism
  • Population-based Surveillance And Outcomes of Venous Thromboembolism
  • Precision Performance of STA® -COAG CONTROL (N + ABN) PLUS ON STA -SATELLITE®
  • Probing the heparin structural elements for high risk of heparin-induced thrombocytopenia (HIT)
  • Probing the heparin structural elements for high risk of heparin-induced thrombocytopenia (HIT)
  • Promoting the Health of Individuals with Clotting Disorders
  • Public Health Surveillance of Bleeding
  • Pulmonary Hypertension in SCD
  • QuBBD: Collaborative Research: Advancing mHealth using Big Data Analytics: Statistical and Dynamical Systems Modeling of Real-Time Adaptive m-Intervention for Pain
  • Randomized double-blind study of FT-4202 in sickle cell disease
  • Rare Thrombotic Diseases Clinical Research Network
  • Relationship of Depression to SCD Severity, Health Care Utilization and QoL
  • Role of Complement Receptors in cellualr activation by HIT immune complexes
  • Role of Erythropoietin Receptor Signaling in the Heart
  • Role of RBC NO and ATP in Sickle Vasculopathy
  • Role of RBC Reactive Oxygen Species and Their Vicious Cycle in Sickle Vasculopathy
  • Role of myeloid KLF2 in antiphospholipid antibody-mediated thrombosis
  • SCH: INT: Collaborative Research: Development and analysis of integrative models for chronic pain
  • SICKLE CELL DISEASE STRUCTURED TRANSITION EDUCATION INTERVENTION WITH PEER MENTORING SUPPORT TO IMPROVING CARE TRANSITIONS (SCD STEP-UP PROGRAM)
  • STA - Coag Control ABN PLUS Precision Study
  • SUCCESSOR Chart Review
  • SUSTAIN (A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SEIGI With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
  • Same
  • Sharing Comprehensive 'Omics in Sickle Cell Disease Through the NHLBI TOPMed Network
  • Shire SC Study (A Phase 1/2 randomized, double-blind, placebo-controlled, multicenter, ascending dose, safety and PK/PD study of SHP655 (rADAMTS13) in sickle cell disease at baseline health and during acute vaso-occlusive crisis.)
  • Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
  • Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
  • Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
  • Sickle Cell Treatment Demonstration
  • Siemans/VWF - Hemosil and REAADS Study
  • Siemens CS-2100i and CS-5100 New Generation Analyzers
  • Stago - STA-NeoPTimal 5ml and 10 ml Single Site Precision Study
  • Stago - STA-NeoPTimal 5ml and 10m: Multisite Precision Study
  • Task Order 1 under Master Eval Agreement #17072705
  • Testing The Effect Of Ferroportin Inhibitor On Sickle Cell Pathophysiology
  • ThRombosis exelUsion STudy for STA - Liatest D-DiXL (TRUST)
  • Thalassemia Screening in Myanmese and Lao Migrants in Thailand
  • The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcomes in the Era of the Novel Agents
  • Thrombosis and Hemostasis Centers Research and Prevention Network
  • Tissue Transglutaminase in Neurologic Injury
  • Transfusion Medicine and Hematology
  • Transfusion Medicine/Hemostasis Core Clinical Center
  • U.S. External Site Protocol for Evaluation of Precision Performances of STA-THROMBIN ON STA-SATELLITE
  • Understanding and Enhancing the Therapeutic Efficacy of Factor VIIa for Emergency Hemostasis
  • Use of Mobile Technology for Intensive Training in Medication Management
  • Use of Mobile Technology to Improve Acute Care Utilization in Sickle Cell Disease
  • Variability in neutrophil activation
  • same

Add data to my Website